Blank

Apoglyx

Apoglyx

  • Home
  • About Us
  • AQUAPORINS
  • R&D Portfolio
  • NEWS
  • CONTACT

RG100204 is effective in a preclinical model of bacterial sepsis

December 21, 2020

New ApoGlyx results demonstrate that RG100204 is effective in reducing organ damage in a preclinical model of bacterial sepsis.

There is currently no specific treatment for sepsis, the body’s overreaction to infection that often causes severe organ damage, and death. According to the Global Sepsis Alliance, 47 to 50 million people are affected by sepsis annually, and more than 11 million of these patients die, even though sepsis is often not mentioned specifically on death certificates.

In a study conducted at the William Harvey Research Institute in London, ApoGlyx obtained results demonstrating effective reduction of organ damage, by the lead compound RG100204.

“The unique observation that we made with RG100204 was that it can improve heart function, and reduce damage to further vital organs, even when the compound was given up to three hours after the induction of sepsis! We have never tried a late administration of a drug at 3h after the onset of sepsis, so the finding that RG100204 is still effective when given at this late stage is impressive”, says Professor Christoph Thiemermann, a renowned expert in the field of sepsis.

Encouraged by the new results in the pre-clinical sepsis model, ApoGlyx is now looking to raise new capital to bring this novel approach forward to first-in-human clinical trials.

BACK

Apoglyx

info@apoglyx.com
c/o Anyo AB
Ideon Science Park
223 70 LUND


Copyright © 2020 ApoGlyx, all rights reserved.

Reg/VAT#s: 556756-7085
VAT: SE556756708501

Content

  • HOME
  • ABOUT US
  • AQUAPORINS
  • R&D PORTFOLIO
  • NEWS
  • CONTACT
  • PATENTS
  • PUBLICATIONS
  • REFERENCES
  • Social Media

  • LinkedIn
  • We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
    Cookie settingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT